The Booming Medical Devices Industry: A Focus on AI and Top Hedge Fund Picks
The healthcare sector relies heavily on advancements in medical technology, particularly devices used for disease prevention, diagnosis, and treatment. Unlike pharmaceuticals, which primarily function through chemical processes, medical devices operate through physical or mechanical means. Key examples include pacemakers, imaging equipment, dialysis machines, and implants.
Impact of COVID-19 and Digital Health Investments
The COVID-19 pandemic significantly impacted the medical device industry, with the In Vitro Diagnostics (IVD) segment experiencing substantial revenue growth in 2020 and 2021 due to the surge in demand for PCR and rapid testing. Although funding for digital health had been steadily increasing in the years leading up to the pandemic, it saw a notable acceleration in 2021, reaching approximately $45 billion – surpassing the total invested between 2010 and 2017.
Global Market Growth and Key Drivers
The global market for medical devices, valued at $570 billion in 2022, is projected to grow at a compound annual growth rate (CAGR) of 5.8% from 2023 to 2032, reaching over $996.93 billion. The U.S. market is expected to expand to approximately $246.51 billion by 2032, with a CAGR of 5.6%. The driving forces behind this expansion include the rising demand for cutting-edge treatments and continuous technological advancements in medical devices to address unmet healthcare needs.
Industry Significance and Importance
The medical device sector’s significance is highlighted by its contribution to the U.S. economy. With over 329,000 employees and $25.8 billion in payroll generated in 2020, it is a major player. This underscores the industry’s importance, as emphasized by the U.S. Cluster Mapping Tool.
AI Revolutionizing Healthcare
Artificial intelligence (AI) is transforming patient monitoring, diagnosis, and treatment in healthcare. AI applications include predicting patient outcomes using electronic health records and analyzing radiological images for early detection. A notable example is the collaboration between NVIDIA Corporation and Medtronic, which integrates NVIDIA’s AI technology into Medtronic’s FDA-approved GI Genius, an intelligent endoscopic module that helps detect precancerous growths.
Top Hedge Fund Picks in Medical Technology
To create our list of the most promising medical stocks, we started by filtering medical stocks from healthcare equipment ETFs. The next step was identifying those with the highest number of hedge fund holders as of Q2 2024, utilizing data from the Insider Monkey database. We then ranked the final selection based on the number of hedge fund holders, prioritizing stocks with higher institutional interest.
Why are we interested in stocks that hedge funds pile into? The reason is simple: Our research shows that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points.see more details here.
Becton, Dickinson and Company (NYSE:BDX) is a global medical technology company that develops, manufactures, and sells a diverse array of medical supplies, devices, laboratory equipment, and diagnostic products. The company provides essential tools and technologies utilized by healthcare professionals, researchers, and patients worldwide.
Becton, Dickinson and Company (NYSE:BDX) offers a range of products, including drug detectors, catheters, inventory optimization systems, and drug collection products. With trailing twelve-month revenues of $19.8 billion and cash equivalents of $1.4 billion, the company benefits from economies of scale that help maintain high margins. However, these economies also require consistent revenue growth to avoid margin compression from high operating expenses. The stock has declined 3.4% year-to-date, primarily due to flat international revenue of $2.1 billion, which accounts for 42% of sales, largely affected by a slowdown in China. Additionally, the company’s pharmaceutical and biomedical segments have not shown growth, leading to a modest 3.2% revenue increase over the nine months ending in June, while expenses rose by 3.5%. To mitigate these challenges, Becton, Dickinson and Company (NYSE:BDX) is focusing on acquisitions. Here’s what management shared on this front during the Q3 2024 earnings call:
“Today, BD has a $4 billion-plus business in health care automation and informatics AI and we’ll increase this to over $5 billion as we complete the acquisition of Critical Care. This expands BD in the smart critical care space and creates new opportunities to combine AI-driven monitoring with systems such as infusion technologies to simplify nursing workflow and improve patient care. Looking ahead to 2030, we view health care process automation and informatics AI as having the potential to become a business exceeding $7 billion as we continue to build more connected, automated, and intelligent solutions to transform the core processes underlying care delivery.”
BDX **ranks 2nd** on our list of the most promising medical stocks according to hedge funds. While we acknowledge the potential of BDX as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns within a shorter timeframe. If you are looking for an AI stock that is more promising than BDX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.